Publications & Posters
Scholarly publications
Facioscapulohumeral Muscular Dystrophy
Neuromuscular
SRK-015
June 2025
FSHD Society International Research Congress
SRK-015 improves muscle mass, strength, and endurance in the FLExDUX4.Cre mouse model of FSHD
Spinal Muscular Atrophy
Apitegromab
March 2025
Muscular Dystrophy Association Clinical & Scientific Conference
Efficacy and safety of apitegromab in individuals with type 2 and type 3 spinal muscular atrophy evaluated in the phase 3 SAPPHIRE trial
Neuromuscular
Apitegromab
March 2025
Muscular Dystrophy Association Clinical & Scientific Conference
SRK-015 builds muscle mass and strength in combination with dystrophin upregulation in a mouse model of DMD
Spinal Muscular Atrophy
Apitegromab
March 2025
Muscular Dystrophy Association Clinical & Scientific Conference
Efficacy and safety of apitegromab in individuals with type 2 and type 3 spinal muscular atrophy evaluated in the phase 3 SAPPHIRE trial
Immuno-Oncology
SRK-181
November 2024
Society for Immunotherapy of Cancer (SITC) 2024
DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor-resistant advanced cancers
Cardiometabolic Disease
SRK-439
November 2024
ObesityWeek 2024
